Novartis AG (NVS)
NYSE: NVS · IEX Real-Time Price · USD
106.13
-1.09 (-1.02%)
At close: Jul 19, 2024, 4:00 PM
108.12
+1.99 (1.88%)
Pre-market: Jul 22, 2024, 7:42 AM EDT
Novartis AG Employees
Novartis AG had 76,057 employees as of December 31, 2023. The number of employees decreased by 25,646 or -25.22% compared to the previous year.
Employees
76,057
Change (1Y)
-25,646
Growth (1Y)
-25.22%
Revenue / Employee
$642,413
Profits / Employee
$212,669
Market Cap
207.64B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 76,057 | -25,646 | -25.22% |
Dec 31, 2022 | 101,703 | -2,620 | -2.51% |
Dec 31, 2021 | 104,323 | -1,471 | -1.39% |
Dec 31, 2020 | 105,794 | 1,880 | 1.81% |
Dec 31, 2019 | 103,914 | -21,247 | -16.98% |
Dec 31, 2018 | 125,161 | 3,564 | 2.93% |
Dec 31, 2017 | 121,597 | 3,204 | 2.71% |
Dec 31, 2016 | 118,393 | -307 | -0.26% |
Dec 31, 2015 | 118,700 | -14,713 | -11.03% |
Dec 31, 2014 | 133,413 | -2,283 | -1.68% |
Dec 31, 2013 | 135,696 | 7,972 | 6.24% |
Dec 31, 2012 | 127,724 | 4,038 | 3.26% |
Dec 31, 2011 | 123,686 | 4,268 | 3.57% |
Dec 31, 2010 | 119,418 | 19,584 | 19.62% |
Dec 31, 2009 | 99,834 | 3,117 | 3.22% |
Dec 31, 2008 | 96,717 | -1,483 | -1.51% |
Dec 31, 2007 | 98,200 | -2,535 | -2.52% |
Dec 31, 2006 | 100,735 | 9,735 | 10.70% |
Dec 31, 2005 | 91,000 | 9,600 | 11.79% |
Dec 31, 2004 | 81,400 | 2,859 | 3.64% |
Dec 31, 2003 | 78,541 | 5,664 | 7.77% |
Dec 31, 2002 | 72,877 | 2,557 | 3.64% |
Dec 31, 2001 | 70,320 | 1,252 | 1.81% |
Dec 31, 2000 | 69,068 | -13,391 | -16.24% |
Dec 31, 1999 | 82,459 | -3,376 | -3.93% |
Dec 31, 1998 | 85,835 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Pfizer | 88,000 |
Merck & Co. | 72,000 |
Danaher | 63,000 |
NVS News
- 3 days ago - Novartis Falls Despite Earnings Beat, Guidance Raise - Investopedia
- 4 days ago - Novartis lifts guidance again as demand climbs for top drugs - Market Watch
- 4 days ago - Novartis raises 2024 profit guidance for second time - Reuters
- 4 days ago - Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance - GlobeNewsWire
- 5 weeks ago - Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment - GlobeNewsWire
- 6 weeks ago - Novartis and others face Italy antitrust probe over eye drug - Reuters
- 7 weeks ago - Novartis leukemia drug more effective than older treatments in trial - Reuters
- 7 weeks ago - Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML - GlobeNewsWire